0O1O.LSE Vetoquinol
- Market cap
- EUR 947M
- P/E
- 15.8x
- P/B
- -
- ROE
- 20.0%
- Dividend yield
- 1.19%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is 0O1O.LSE undervalued?
Graham numberThe Graham number of Vetoquinol cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Vetoquinol fundamental analysis
No fundamental analysis for Vetoquinol yet.
Vetoquinol stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Vetoquinol
Vetoquinol SA, a veterinary pharmaceutical company, engages in designing, developing, and selling of veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal medicine; and cardio-nephrology. The company was founded in …
Full company profileVetoquinol financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Vetoquinol annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 350M | 352M | 368M | 396M | 427M | 521M | 540M | 529M | 539M | 526M | 1.04B |
| Gross Profit | 132M | 109M | 115M | 113M | 124M | 167M | 172M | 291M | 159M | 160M | 154M |
| Operating Income | 36.9M | 40.3M | 43.3M | 41.8M | 52.5M | 77.3M | 79.3M | 74.3M | 70.3M | 73.2M | 148M |
| EBITDA | 50.0M | 51.9M | 57.3M | 58.8M | 59.3M | 117M | 108M | 103M | 109M | 105M | 212M |
| Net Income | 27.8M | 34.8M | 36.3M | 28.6M | 19.2M | 62.9M | 48.0M | 55.6M | 58.7M | 57.3M | 122M |
| EPS | 2.35 | 2.94 | 3.06 | 2.42 | 1.63 | 5.31 | 4.06 | 4.70 | 4.98 | 4.82 | 10 |
| Balance Sheet | |||||||||||
| Total Assets | 439M | 444M | 466M | 511M | 646M | 625M | 652M | 692M | 744M | 764M | 771M |
| Total Liabilities | 122M | 108M | 102M | 125M | 274M | 183M | 167M | 165M | 168M | 172M | 162M |
| Shareholders' Equity | 316M | 336M | 363M | 386M | 372M | 441M | 485M | 527M | 576M | 591M | 609M |
| Cash & Short-term Investments | 103M | 113M | 118M | 84.5M | 129M | 69.0M | 93.7M | 147M | 206M | 221M | 235M |
| Total Debt | 24.3M | 15.4M | 6.67M | 12.1M | 125M | 15.4M | 17.4M | 17.6M | 21.1M | 15.3M | 12.4M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 43.7M | 41.2M | 37.9M | 52.0M | 92.2M | 89.7M | 62.9M | 89.4M | 90.4M | 76.0M | 162M |
| Capital Expenditure | 13.6M | 13.7M | 14.2M | 9.45M | 10.3M | 13.8M | 17.0M | 14.9M | 14.5M | 17.0M | 25.6M |
| Free Cash Flow | 30.1M | 27.5M | 23.7M | 42.6M | 81.9M | 75.9M | 45.9M | 74.5M | 75.9M | 59.0M | 136M |
| Ratios | |||||||||||
| ROE | 8.8% | 10.4% | 10.0% | 7.4% | 5.2% | 14.2% | 9.9% | 10.5% | 10.2% | 9.7% | 20.0% |
| ROA | 6.3% | 7.8% | 7.8% | 5.6% | 3.0% | 10.1% | 7.4% | 8.0% | 7.9% | 7.5% | 15.8% |
| Net Profit Margin | 7.9% | 9.9% | 9.9% | 7.2% | 4.5% | 12.1% | 8.9% | 10.5% | 10.9% | 10.9% | 11.8% |
| Debt to Equity | 0.08x | 0.05x | 0.02x | 0.03x | 0.34x | 0.03x | 0.04x | 0.03x | 0.04x | 0.03x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Vetoquinol dividends
- Dividend yield
- 1.19%
- Forward dividend
- -
- Payout ratio
- 18.2%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | 10.4M | 0.88 | 18.2% |
| 2024 | EUR 10.1M | 0.85 | 17.1% |
| 2023 | EUR 9.47M | 0.80 | 17.0% |
| 2022 | EUR 9.47M | 0.80 | 19.7% |
| 2021 | EUR 5.91M | 0.50 | 9.4% |
| 2020 | EUR 4.49M | 0.38 | 23.4% |
| 2019 | EUR 5.68M | 0.48 | 19.9% |
| 2018 | EUR 5.46M | 0.46 | 15.0% |
| 2017 | EUR 5.10M | 0.43 | 14.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Vetoquinol
- Insiders 67.01%
- Institutions 11.71%
- Public & others 21.28%
- Shares outstanding 11.9M
- Free float 3.65M
Vetoquinol company profile
- Company name
- Vetoquinol
- Ticker
- 0O1O.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 2,526
- Fiscal year end
- December
- Address
- Magny-Vernois, Lure, France, 70204
- Phone
- 33 3 84 62 55 55
- Website
- vetoquinol.com
About Vetoquinol
Vetoquinol SA, a veterinary pharmaceutical company, engages in designing, developing, and selling of veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal medicine; and cardio-nephrology. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA operates as a subsidiary of Soparfin SCA.
Vetoquinol management
9- Mr. Matthieu FrechinCEO & Non-Independent Chairman of the Board · born 1969
- Mr. Dominique DerveauxChief Operations Officer & Group Deputy CEO · born 1969
- Mr. Alain MassonDeputy CEO & Pharmacist Manager · born 1962
- Mr. Regis Vimal du MonteilChief Financial Officer · born 1965
- Philippe GruetChief Scientific Officer
- Sandrine PerrierChief Information Officer
- Laurent ThoreDirector of Partnerships, Legal Affairs & Risks
- Xavier BerthetDirector of Group Communications
- Ms. Nathalie ArlecchiniGroup Human Resources Director